Abstract
BackgroundPhysical activity after cancer diagnosis improves quality of life and may lengthen survival. However, objective data in cancer survivors are limited and no physical activity tracker has been validated for use in this population.ObjectiveThe aim of this study was to validate the Fitbit One’s measures of physical activity over 7 days in free-living men with localized prostate cancer.MethodsWe validated the Fitbit One against the gold-standard ActiGraph GT3X+ accelerometer in 22 prostate cancer survivors under free-living conditions for 7 days. We also compared these devices with the HJ-322U Tri-axis USB Omron pedometer and a physical activity diary. We used descriptive statistics (eg, mean, standard deviation, median, interquartile range) and boxplots to examine the distribution of average daily light, moderate, and vigorous physical activity and steps measured by each device and the diary. We used Pearson and Spearman rank correlation coefficients to compare measures of physical activity and steps between the devices and the diary.ResultsOn average, the men wore the devices for 5.8 days. The mean (SD) moderate-to-vigorous physical activity (MVPA; minutes/day) measured was 100 (48) via Fitbit, 51 (29) via ActiGraph, and 110 (78) via diary. The mean (SD) steps/day was 8724 (3535) via Fitbit, 8024 (3231) via ActiGraph, and 6399 (3476) via pedometer. Activity measures were well correlated between the Fitbit and ActiGraph: 0.85 for MPVA and 0.94 for steps (all P<.001). The Fitbit’s step measurements were well correlated with the pedometer (0.67, P=.001), and the Fitbit’s measure of MVPA was well correlated with self-reported activity in the diary (0.84; P<.001).ConclusionsAmong prostate cancer survivors, the Fitbit One’s activity and step measurements were well correlated with the ActiGraph GT3X+ and Omron pedometer. However, the Fitbit One measured two times more MVPA on average compared with the ActiGraph.
Highlights
IntroductionObjective: The aim of this study was to validate the Fitbit One’s measures of physical activity over 7 days in free-living men with localized prostate cancer
Prostate cancer is the most commonly diagnosed invasive cancer and the second leading cause of cancer death among men in the United States
We used descriptive statistics and boxplots to examine the distribution of average daily light, moderate, and vigorous physical activity and steps measured by each device and the diary
Summary
Objective: The aim of this study was to validate the Fitbit One’s measures of physical activity over 7 days in free-living men with localized prostate cancer. Methods: We validated the Fitbit One against the gold-standard ActiGraph GT3X+ accelerometer in 22 prostate cancer survivors under free-living conditions for 7 days. We compared these devices with the HJ-322U Tri-axis USB Omron pedometer and a physical activity diary. The mean (SD) moderate-to-vigorous physical activity (MVPA; minutes/day) measured was 100 (48) via Fitbit, 51 (29) via ActiGraph, and 110 (78) via diary. Conclusions: Among prostate cancer survivors, the Fitbit One’s activity and step measurements were well correlated with the ActiGraph GT3X+ and Omron pedometer. The Fitbit One measured two times more MVPA on average compared with the ActiGraph
Sign-in/Register to view highlights & summary 
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call